|
1
|
Pavlidis N, Briasoulis E, Hainsworth J and
Greco FA: Diagnostic and therapeutic management of cancer of an
unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Le Chevalier T, Cvitkovic E, Caille P,
Harvey J, Contesso G, Spielmann M and Rouesse J: Early metastatic
cancer of unknown primary origin at presentation. A clinical study
of 302 consecutive autopsied patients. Arch Intern Med.
148:2035–2039. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hainsworth JD, Spigel DR, Clark BL,
Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM,
Cescon T, Bury MJ and Greco FA: Paclitaxel/carboplatin/etoposide
versus gemcitabine/irinotecan in the first-line treatment of
patients with carcinoma of unknown primary site: a randomized,
phase III Sarah Cannon Oncology Research Consortium Trial. Cancer
J. 16:70–75. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Møller AK, Pedersen KD, Gothelf A and
Daugaard G: Paclitaxel, cisplatin and gemcitabine in treatment of
carcinomas of unknown primary site, a phase II study. Acta Oncol.
49:423–430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fernandez-Cotarelo MJ, Guerra-Vales JM,
Colina F and de la Cruz J: Prognostic factors in cancer of unknown
primary site. Tumori. 96:111–116. 2010.PubMed/NCBI
|
|
6
|
Hainsworth JD, Daugaard G, Lesimple T,
Hübner G, Greco FA, Stahl MJ, Büschenfelde CM, Allouache D, Penel
N, Knoblauch P and Fizazi KS: Paclitaxel/carboplatin with or
without belinostat as empiric first-line treatment for patients
with carcinoma of unknown primary site: a randomized, phase 2
trial. Cancer. 121:1654–1661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang SW, Hsu CM, Jeng WJ, Yen TC, Su MY
and Chiu CT: A comparison of positron emission tomography and
colonoscopy for the detection of advanced colorectal neoplasms in
subjects undergoing a health check-up. PLoS One. 8:e691112013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun N, Zhao J, Qiao W and Wang T:
Predictive value of interim PET/CT in DLBCL treated with R-CHOP:
meta-analysis. Biomed Res Int. 2015:6485722015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin J, Kligerman S, Goel R, Sajedi P,
Suntharalingam M and Chuong MD: State-of-the-art molecular imaging
in esophageal cancer management: implications for diagnosis,
prognosis, and treatment. J Gastrointest Oncol. 6:3–19.
2015.PubMed/NCBI
|
|
10
|
Os AA, Fischbein NJ, Caputo GR, Kaplan MJ,
Price DC, Singer MI, Dillon WP and Hawkins RA: Metastatic head and
neck cancer: role and usefulness of FDG PET in locating occult
primary tumors. Radiology. 210:177–181. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nassenstein K, Veit-Haibach P, Stergar H,
Gutzeit A, Freudenberg L, Kuehl H, Fischer M, Barkhausen J,
Bockisch A and Antoch G: Cervical lymph node metastases of unknown
origin: primary tumor detection with whole-body positron emission
tomography/computed tomography. Acta Radiol. 48:1101–1108. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang G, Wu Y, Zhang W, Li J, Wu P and Xie
C: Clinical value of whole-body F-18 fluorodeoxyglucose positron
emission tomography/computed tomography in patients with carcinoma
of unknown primary. J Med Imaging Radiat Oncol. 57:65–71. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JR, Kim JS, Roh JL, Lee JH, Baek JH,
Cho KJ, Choi SH, Nam SY and Kim SY: Detection of occult primary
tumors in patients with cervical metastases of unknown primary
tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or
CT/MR imaging-prospective study. Radiology. 274:764–771. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Elboga U, Kervancioglu S, Sahin E,
Basibuyuk M, Celen YZ and Aktolun C: Utility of F-18
fluorodeoxyglucose positron emission tomography/computed in
carcinoma of unknown primary. Int J Clin Exp Pathol. 7:8941–8946.
2014.PubMed/NCBI
|
|
15
|
Breuer N, Behrendt FF, Heinzel A, Mottaghy
FM, Palmowski M and Verburg FA: Prognostic relevance of (18)F-FDG
PET/CT in carcinoma of unknown primary. Clin Nucl Med. 39:131–135.
2014.PubMed/NCBI
|
|
16
|
Hu M, Zhao W, Zhang PL, Ju GF, Fu Z, Zhang
GL, Kong L, Yang YQ, Ma YD and Yu JM: Clinical applications of
18F-fluorodeoxyglucose positron emission tomography/computed
tomography in carcinoma of unknown primary. Chin Med J (Engl).
124:1010–1014. 2011.PubMed/NCBI
|
|
17
|
Pak K, Kim SJ, Kim IJ, Nam HY, Kim BS, Kim
K and Kim YK: Clinical implication of (18)F-FDG PET/CT in carcinoma
of unknown primary. Neoplasma. 58:135–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yabuki K, Tsukuda M, Horiuchi C, Taguchi T
and Nishimura G: Role of 18F-FDG PET in detecting primary site in
the patient with primary unknown carcinoma. Eur Arch
Otorhinolaryngol. 267:1785–1792. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chorost MI, Lee MC, Yeoh CB, Molina M and
Ghosh BC: Unknown primary. J Surg Oncol. 87:191–203. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pelosi E, Pennone M, Deandreis D,
Douroukas A, Mancini M and Bisi G: Role of whole body positron
emission tomography/computed tomography scan with
18F-fluorodeoxyglucose in patients with biopsy proven tumor
metastases from unknown primary site. Q J Nucl Med Mol Imaging.
50:15–22. 2006.PubMed/NCBI
|
|
21
|
Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX
and Liu ZF: Role of fluorodeoxyglucose-PET versus
fluorodeoxyglucose-PET/computed tomography in detection of unknown
primary tumor: a meta-analysis of the literature. Nucl Med Commun.
29:791–802. 2008.PubMed/NCBI
|
|
22
|
Wu ZJ, Zhang YX, Wei H and Jia Q: The role
of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron
emission tomography/computed tomography in the management of
unknown primary tumors. Zhonghua Yi Xue Za Zhi. 87:2253–2256.
2007.(In Chinese). PubMed/NCBI
|
|
23
|
Ryu IS, Choi SH, Kim do H, Han MW, Roh JL,
Kim SY and Nam SY: Detection of the primary lesion in patients with
cervical metastases from unknown primary tumors with narrow band
imaging endoscopy: preliminary report. Head Neck. 35:10–14. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao K, Luo XM, Zhou SH, Liu JH, Yan SX,
Lu ZJ, Yang SY, Lin LL and Dong MJ:
18F-fluorodeoxyglucose positron emission
tomography/computed tomography as an effective diagnostic workup in
cervical metastasis of carcinoma from an unknown primary tumor.
Cancer Biother Radiopharm. 27:685–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Vries E and Coebergh JW: Melanoma
incidence has risen in Europe. BMJ. 331:6982005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rohren EM: PET/Computed tomography and
patient outcomes in melanoma. PET Clin. 10:243–254. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Katz KA, Jonasch E, Hodi FS, Soiffer R,
Kwitkiwski K, Sober AJ and Haluska FG: Melanoma of unknown primary:
experience at Massachusetts General Hospital and Dana-Farber Cancer
Institute. Melanoma Res. 15:77–82. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krug B, Crott R, Lonneux M, Baurain JF,
Pirson AS and Borght T Vander: Role of PET in the initial staging
of cutaneous malignant melanoma: systematic review. Radiology.
249:836–844. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schwenzer NF and Pfannenberg AC: PET/CT,
MR, and PET/MR in lymphoma and melanoma. Semin Nucl Med.
45:322–331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bertozzi S, Londero AP, Petri R and
Bernardi S: Isolated axillary nodal swelling and cancer of unknown
primary. Eur J Gynaecol Oncol. 36:131–137. 2015.PubMed/NCBI
|
|
31
|
Tardivon AA, Athanasiou A, Thibault F and
El Khoury C: Breast imaging and reporting data system (BIRADS)
magnetic resonance imaging illustrated cases. Eur J Radiol.
61:216–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mahoney MC, Gatsonis C, Hanna L, DeMartini
WB and Lehman C: Positive predictive value of BI-RADS MR imaging.
Radiology. 264:51–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
